Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics

WM Oo, SPC Yu, MS Daniel… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: Osteoarthritis (OA) is a leading cause of pain and disability among adults with a
current prevalence of around 15% and a predicted prevalence of 35% in 2030 for …

The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis—a systematic review and network meta-analysis

W Yang, C Sun, SQ He, JY Chen, Y Wang… - Journal of General …, 2021 - Springer
Background Osteoarthritis (OA) is common and burdensome for patients and health care
systems. Our study purpose was to evaluate the long-term efficacy and safety of DMOADs in …

[HTML][HTML] Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis Knee Score)

DJ Hunter, A Guermazi, GH Lo, AJ Grainger… - Osteoarthritis and …, 2011 - Elsevier
OBJECTIVE: In an effort to evolve semi-quantitative scoring methods based upon limitations
identified in existing tools, integrating expert readers' experience with all available scoring …

[HTML][HTML] EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis

G Sakellariou, PG Conaghan, W Zhang… - Annals of the …, 2017 - ard.bmj.com
The increased information provided by modern imaging has led to its more extensive use.
Our aim was to develop evidence-based recommendations for the use of imaging in the …

Toward classification criteria for early osteoarthritis of the knee

FP Luyten, S Bierma-Zeinstra, F Dell'Accio… - Seminars in arthritis and …, 2018 - Elsevier
Objective To propose draft classification criteria for early stage osteoarthritis (OA) of the knee
for use in a primary care setting. Methods A group of basic scientists, physician-scientists …

Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double‐blind, placebo‐controlled trial

LS Lohmander, S Hellot, D Dreher… - Arthritis & …, 2014 - Wiley Online Library
Objective To evaluate the efficacy and safety of intraarticular sprifermin (recombinant human
fibroblast growth factor 18) in the treatment of symptomatic knee osteoarthritis (OA). Methods …

Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a …

D Buendía-López, M Medina-Quirós… - Journal of Orthopaedics …, 2018 - Springer
Background Knee osteoarthritis (OA) is a disease with a high prevalence in the adult
population. Nonsteroidal anti-inflammatory drugs (NSAID) or intra-articular injections …

Biomarkers for osteoarthritis: current position and steps towards further validation

DJ Hunter, M Nevitt, E Losina, V Kraus - Best practice & research Clinical …, 2014 - Elsevier
Historically disease knowledge development and treatment innovation in osteoarthritis (OA)
has been considered to be slow. One of the many reasons purported as responsible for this …

Lorecivivint, a novel Intraarticular CDC‐like kinase 2 and dual‐specificity tyrosine phosphorylation‐regulated kinase 1A inhibitor and Wnt pathway modulator for the …

Y Yazici, TE McAlindon, A Gibofsky… - Arthritis & …, 2020 - Wiley Online Library
Objective To assess the safety and efficacy of a novel Wnt pathway modulator, lorecivivint
(SM 04690), for treating pain and inhibiting structural progression in moderately to severely …

Lateral wedge insoles for medial knee osteoarthritis: 12 month randomised controlled trial

KL Bennell, KA Bowles, C Payne, F Cicuttini… - Bmj, 2011 - bmj.com
Objective To assess the effect of lateral wedge insoles compared with flat control insoles on
improving symptoms and slowing structural disease progression in medial knee …